Johnson & Johnson vs. Mineralys Therapeutics, Inc. Common Stock
JNJ
Johnson & Johnson
$278.43 +1.17%
VS MLYSMineralys Therapeutics, Inc. Common Stock
$28.27 -2.65%
Johnson & Johnson (JNJ) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| JNJ | MLYS | |
|---|---|---|
| Market Cap | $663.23 billion | $2.50 billion |
| Revenue (TTM) | $97.93 billion | — |
| Net Income (TTM) | $21.04 billion | $-349,576,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | MLYS | |
|---|---|---|
| P/E Ratio | 32.30 | — |
| Price / Book | 7.81 | 4.54 |
| Price / Sales | 6.77 | — |
MLYS leads on 1 of 1 valuation factors.
Profitability
| JNJ | MLYS | |
|---|---|---|
| Net Margin | 21.48% | — |
| Return on Equity | 24.76% | -63.45% |
JNJ leads on 1 of 1 profitability factors.
Dividend
| JNJ | MLYS | |
|---|---|---|
| Dividend Yield | 1.93% | — |
| Payout Ratio | 62.18 | — |
JNJ and MLYS split the dividend factors evenly.
Risk & Sentiment
| JNJ | MLYS | |
|---|---|---|
| Short Interest | 0.67% | 0.06% |
MLYS leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, MLYS overview, MLYS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.